Results 1 to 10 of about 518,556 (268)

Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients

Breast Cancer Research, 2021
Background Following the PALOMA-3 study results, the combination of palbociclib, a CDK4/6 inhibitor, with fulvestrant, a selective estrogen receptor degrader, has become a standard therapy in women with estrogen receptor-positive (ER+) HER2-negative ...
Lauren Darrigues, Jean-Yves Pierga, Alice Bernard-Tessier, Ivan Bièche, Amanda Bartolini Silveira, Marc Michel, Delphine Loirat, Paul Cottu, Luc Cabel, Coraline Dubot, Romain Geiss, Francesco Ricci, Anne Vincent-Salomon, Charlotte Proudhon, François-Clément Bidard   +14 more
doaj   +1 more source

Molecular and Circulating Biomarkers of Brain Tumors [PDF]

International Journal of Molecular Sciences, 2021
Brain tumors are the most common malignant primary intracranial tumors of the central nervous system. They are often recognized too late for successful therapy. Minimally invasive methods are needed to establish a diagnosis or monitor the response to treatment of CNS tumors. Brain tumors release molecular information into the circulation.
Wojciech Jelski, Barbara Mroczko
openaire   +3 more sources

Biomarkers of Tumor Metastasis and Invasiveness

Cancers, 2023
The identification of proteins as new cancer diagnostic and prognostic biomarkers continues to attract considerable attention in the oncology literature, especially in the context of invasion and metastasis activation process [...]
Daniel L. Pouliquen, Cristina Núñez González   +1 more
openaire   +3 more sources

The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma

Scientific Reports, 2023
Renal cancer cells constitute a paradigm of tumor cells with a glycolytic reprogramming which drives metabolic alterations favouring cell survival and transformation.
Caroline E. Nunes-Xavier, Maite Emaldi, Janire Mingo, Tove Øyjord, Gunhild M. Mælandsmo, Øystein Fodstad, Peio Errarte, Gorka Larrinaga, Roberto Llarena, José I. López, Rafael Pulido   +10 more
doaj   +1 more source

Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer

Frontiers in Oncology, 2022
BackgroundPyruvate dehydrogenase (PDH) complex converts pyruvate into acetyl-CoA by pyruvate decarboxylation, which drives energy metabolism during cell growth, including prostate cancer (PCa) cell growth.
Caroline E. Nunes-Xavier, Caroline E. Nunes-Xavier, Janire Mingo, Maite Emaldi, Karine Flem-Karlsen, Gunhild M. Mælandsmo, Øystein Fodstad, Roberto Llarena, José I. López, José I. López, Rafael Pulido, Rafael Pulido   +11 more
doaj   +1 more source

A Diagnostic Model With IgM Autoantibodies and Carcinoembryonic Antigen for Early Detection of Lung Adenocarcinoma

Frontiers in Immunology, 2022
Immunoglobulin M (IgM) autoantibodies, as the early appearing antibodies in humoral immunity when stimulated by antigens, might be excellent biomarkers for the early detection of lung cancer (LC).
Xue Zhang, Xue Zhang, Jiaqi Li, Jiaqi Li, Yulin Wang, Yulin Wang, Man Liu, Man Liu, Fenghui Liu, Xiuzhi Zhang, Lu Pei, Tingting Wang, Di Jiang, Di Jiang, Xiao Wang, Xiao Wang, Jianying Zhang, Jianying Zhang, Liping Dai, Liping Dai   +19 more
doaj   +1 more source

Identification of novel biomarkers with potential for diagnosis and prognosis of gastric cancer: a Bioinformatics Approach

ABCS Health Sciences, 2023
Introduction: Gastric cancer (GC) is the fifth most diagnosed neoplasia and the third leading cause of cancer-related deaths. A substantial number of patients exhibit an advanced GC stage once diagnosed.
Marcos Vinicius Rossetto, Fernanda Pessi de Abreu, Pedro Lenz Casa, Ivaine Tais Sauthier Sartor, Scheila de Avila e Silva   +4 more
doaj   +3 more sources

Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer

npj Breast Cancer, 2021
Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) are two cancer-derived blood biomarkers that inform on patient prognosis and treatment efficacy in breast cancer.
Amanda Bortolini Silveira, François-Clément Bidard, Marie-Laure Tanguy, Elodie Girard, Olivier Trédan, Coraline Dubot, William Jacot, Anthony Goncalves, Marc Debled, Christelle Levy, Jean-Marc Ferrero, Christelle Jouannaud, Maria Rios, Marie-Ange Mouret-Reynier, Florence Dalenc, Caroline Hego, Aurore Rampanou, Benoit Albaud, Sylvain Baulande, Frédérique Berger, Jérôme Lemonnier, Shufang Renault, Isabelle Desmoulins, Charlotte Proudhon, Jean-Yves Pierga   +24 more
doaj   +1 more source

A DNA methylation-based liquid biopsy for triple-negative breast cancer

npj Precision Oncology, 2021
Here, we present a next-generation sequencing (NGS) methylation-based blood test called methylation DETEction of Circulating Tumour DNA (mDETECT) designed for the optimal detection and monitoring of metastatic triple-negative breast cancer (TNBC).
Katrina Cristall, Francois-Clement Bidard, Jean-Yves Pierga, Michael J. Rauh, Tatiana Popova, Clara Sebbag, Olivier Lantz, Marc-Henri Stern, Christopher R. Mueller   +8 more
doaj   +1 more source

Renal tumor biomarkers (Review)

Experimental and Therapeutic Medicine, 2021
One of the most common types of cancer worldwide (9th most commonly diagnosed) is renal cell carcinoma (RCC). It is more common in developed countries and it usually develops in individuals between 60 and 70 years of age. The earlier the disease is identified, the lower the morbidity.
Ovidiu, Bratu, Dan, Mischianu, Dragos, Marcu, Dan, Spinu, Lucian, Iorga, Alexandru, Cherciu, Irina, Balescu, Nicolae, Bacalbasa, Camelia, Diaconu, Cornel, Savu, Carmen, Savu, Radu, Anghel   +11 more
openaire   +3 more sources